Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of YH4808 New Formulation in Healthy Subjects
NCT02176668Phase 1Completed
- Sponsor
- Yuhan
- Start
- Jun 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of YH4808 in gastroesophageal reflux disease (GERD) and Peptic ulcer disease (PUD) (10 arms), sponsored by Yuhan. Primary endpoints: Maximum Plasma Concentration of YH4808 at Day 7, Area Under the Curve 0-24h of YH4808 at Day 7 and 2 more. Started Jun 2014; status: completed.
02
Drugs
YH4808
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT02176668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176668.